Mesoblast (NASDAQ:MESO) Stock Price Passes Below Fifty Day Moving Average – Time to Sell?

Mesoblast Limited (NASDAQ:MESO) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $17.19 and traded as low as $15.02. Mesoblast shares last traded at $15.07, with a volume of 129,446 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mesoblast presently has an average rating of “Moderate Buy”.

Mesoblast Stock Down 3.5%

The business’s 50-day moving average is $17.12 and its two-hundred day moving average is $16.86. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -16.53 and a beta of 2.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58.

Mesoblast (NASDAQ:MESO) last issued its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $25.67 million for the quarter. On average, equities analysts anticipate that Mesoblast Limited will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Mesoblast

Several institutional investors and hedge funds have recently made changes to their positions in MESO. Legal & General Group Plc raised its stake in Mesoblast by 4.2% during the 4th quarter. Legal & General Group Plc now owns 679,023 shares of the company’s stock worth $12,237,000 after buying an additional 27,607 shares during the period. Goldman Sachs Group Inc. acquired a new position in Mesoblast in the first quarter valued at about $3,209,000. Bank of America Corp DE increased its holdings in shares of Mesoblast by 791.7% in the third quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock worth $1,796,000 after acquiring an additional 98,960 shares in the last quarter. Rialto Wealth Management LLC bought a new stake in shares of Mesoblast in the fourth quarter worth about $839,000. Finally, Brooklyn Investment Group acquired a new stake in shares of Mesoblast during the third quarter worth about $655,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.